211 related articles for article (PubMed ID: 32670887)
1. Prognostic and Clinicopathological Value of Programmed Cell Death Ligand1 Expression in Patients With Small Cell Lung Cancer: A Meta-Analysis.
Cai H; Zhang H; Jiang Y
Front Oncol; 2020; 10():1079. PubMed ID: 32670887
[No Abstract] [Full Text] [Related]
2. The Clinicopathological and Prognostic Value of PD-L1 Expression in Cholangiocarcinoma: A Meta-Analysis.
Xu G; Sun L; Li Y; Xie F; Zhou X; Yang H; Du S; Xu H; Mao Y
Front Oncol; 2019; 9():897. PubMed ID: 31620360
[No Abstract] [Full Text] [Related]
3. Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis.
Pan ZK; Ye F; Wu X; An HX; Wu JX
J Thorac Dis; 2015 Mar; 7(3):462-70. PubMed ID: 25922726
[TBL] [Abstract][Full Text] [Related]
4. The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta-analysis of 50 studies with 11,383 patients.
Li H; Xu Y; Wan B; Song Y; Zhan P; Hu Y; Zhang Q; Zhang F; Liu H; Li T; Sugimura H; Cappuzzo F; Lin D; Lv T;
Transl Lung Cancer Res; 2019 Aug; 8(4):429-449. PubMed ID: 31555517
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and Clinicopathological Significance of PD-L1 in Patients With Bladder Cancer: A Meta-Analysis.
Zhu L; Sun J; Wang L; Li Z; Wang L; Li Z
Front Pharmacol; 2019; 10():962. PubMed ID: 31616289
[No Abstract] [Full Text] [Related]
6. The prevalence and prognostic and clinicopathological value of PD-L1 and PD-L2 in renal cell carcinoma patients: a systematic review and meta-analysis involving 3,389 patients.
Lu Y; Song Y; Xu Y; Ou N; Liang Z; Hu R; Zhang W; Kang J; Wang X; Liu L; Yang Y; Liu X
Transl Androl Urol; 2020 Apr; 9(2):367-381. PubMed ID: 32420142
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and Clinicopathological Role of PD-L1 in Endometrial Cancer: A Meta-Analysis.
Lu L; Li Y; Luo R; Xu J; Feng J; Wang M
Front Oncol; 2020; 10():632. PubMed ID: 32426281
[No Abstract] [Full Text] [Related]
8. The prognostic value of programmed cell death ligand 1 expression in non-Hodgkin lymphoma: a meta-analysis.
Zhao S; Zhang M; Zhang Y; Meng H; Wang Y; Liu Y; Jing J; Huang L; Sun M; Zhang Y; Zhang Q
Cancer Biol Med; 2018 Aug; 15(3):290-298. PubMed ID: 30197796
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of Programmed Cell Death 1 Ligand-1 in Patients With Bone and Soft Tissue Sarcomas: A Systemic and Comprehensive Meta-Analysis Based on 3,680 Patients.
Wang F; Yu T; Ma C; Yuan H; Zhang H; Zhang Z
Front Oncol; 2020; 10():749. PubMed ID: 32582532
[No Abstract] [Full Text] [Related]
10. The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis.
Li Y; Huang Q; Zhou Y; He M; Chen J; Gao Y; Wang X
Front Pharmacol; 2018; 9():1494. PubMed ID: 30733677
[No Abstract] [Full Text] [Related]
11. Clinicopathological and prognostic significance of PD-L1 expression in sarcoma: A systematic review and meta-analysis.
Zheng C; You W; Wan P; Jiang X; Chen J; Zheng Y; Li W; Tan J; Zhang S
Medicine (Baltimore); 2018 Jun; 97(25):e11004. PubMed ID: 29923984
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and clinicopathological value of PD-L1 in colorectal cancer: a systematic review and meta-analysis.
Yang L; Xue R; Pan C
Onco Targets Ther; 2019; 12():3671-3682. PubMed ID: 31190869
[No Abstract] [Full Text] [Related]
13. The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Li Y; He M; Zhou Y; Yang C; Wei S; Bian X; Christopher O; Xie L
Front Pharmacol; 2019; 10():139. PubMed ID: 30873025
[No Abstract] [Full Text] [Related]
14. Prognostic Value of Programmed Cell Death Ligand-1 Expression in Nasopharyngeal Carcinoma: A Meta-Analysis of 1,315 Patients.
Liu X; Shan C; Song Y; Du J
Front Oncol; 2019; 9():1111. PubMed ID: 31709181
[No Abstract] [Full Text] [Related]
15. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
16. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
[TBL] [Abstract][Full Text] [Related]
17. The clinicopathological and prognostic value of programmed death-ligand 1 in colorectal cancer: a meta-analysis.
Ni X; Sun X; Wang D; Chen Y; Zhang Y; Li W; Wang L; Suo J
Clin Transl Oncol; 2019 May; 21(5):674-686. PubMed ID: 30392153
[TBL] [Abstract][Full Text] [Related]
18. The clinicopathological significance and prognostic value of programmed death-ligand 1 in prostate cancer: a meta-analysis of 3133 patients.
Shen H; Liu J; Sun G; Yan L; Li Q; Wang Z; Xie L
Aging (Albany NY); 2020 Dec; 13(2):2279-2293. PubMed ID: 33318295
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 and prognosis in patients with malignant pleural mesothelioma: a meta-analysis and bioinformatics study.
Jin L; Gu W; Li X; Xie L; Wang L; Chen Z
Ther Adv Med Oncol; 2020; 12():1758835920962362. PubMed ID: 33062064
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis.
Xian F; Ren D; Bie J; Xu G
Front Immunol; 2023; 14():1119168. PubMed ID: 37138876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]